Is stopping secondary prophylaxis safe in HIV-positive talaromycosis patients? Experience from Myanmar.
Ni Ni TunA McleanX DeedM HlaingY AungE WilkinsE AshleyF SmithuisPublished in: HIV medicine (2020)
Secondary prophylaxis can be safely stopped in patients with talaromycosis after immune reconstitution with a sustained increase in CD4 count to ≥ 100 cells/µL after highly active antiretroviral therapy.
Keyphrases
- hiv positive
- antiretroviral therapy
- hiv infected
- men who have sex with men
- human immunodeficiency virus
- end stage renal disease
- south africa
- hiv infected patients
- hiv aids
- ejection fraction
- induced apoptosis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- cell cycle arrest
- cell death
- peripheral blood
- nk cells